Company Analysis
Sign in

GH Research PLC (GHRS)

Nasdaq: GHRS · Pharmaceutical Preparations · Dublin 2, IE · filing with the SEC since 2021
Full chart Alerts Compare
Grade6.3
◀ Past 6.5● Present 6.2▶ Future 6.2
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$48.3M-23.9%
Earnings per share$-0.79-5.3%
Operating cash flow-$43.6M-3.0%
Cash$246M+144.3%
Debt$0.00
Shareholders’ equity$280M+56.3%
Shares, diluted61.0M+17.3%
Return on equity-17.3%
The recordfrom its filings
Filings in 202646
Newest filingNov 5 · SCHEDULE 13G/A
Annual reportMar 5, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryAccelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Sep 9, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 13, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton GHRS · research, not advice